U.S. Markets closed
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • Dow 30

    34,258.32
    +338.48 (+1.00%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • Russell 2000

    2,218.56
    +32.38 (+1.48%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    42,638.06
    +125.63 (+0.30%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Alexion's Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder

·1 min read
  • Alexion Pharmaceuticals Inc (NASDAQ: ALXN) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).

  • The study met its primary endpoint, with a statistically significant change in MG-ADL score from baseline through Week 26 for Ultomiris compared to placebo (-3.1 versus -1.4).

  • Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) is a patient-reported scale to assess MG symptoms and their effects on daily activities.

  • 30% of Ultomiris patients experienced an improvement of at least 5 points in their MG clinical severity score than 11.3% on placebo.

  • These improvements were observed as early as Week 1 and were sustained through Week 26.

  • The proportion of patients who improved at least 3 points in MG-ADL score (56.7% versus 34.1% placebo) was not considered statistically significant.

  • On the safety front, the most frequently observed adverse events were headache (Ultomiris: 18.6%; placebo: 25.8%), diarrhea (15.1% vs. 12.4%), and nausea (10.5% vs. 10.1%).

  • The most frequently observed serious adverse events were MG crisis (Ultomiris: 1.2%) and MG worsening (placebo: 3.4%).

  • Alexion plans to submit regulatory filings in the U.S., European Union, and Japan in late 2021/early 2022.

  • Price Action: ALXN shares closed at $180.51 on Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.